{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:06:42Z","timestamp":1793387202041,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.esmoop.2024.103373","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T17:13:10Z","timestamp":1715101990000},"page":"103373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers"],"prefix":"10.1016","volume":"9","author":[{"given":"L.","family":"Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0776-7477","authenticated-orcid":false,"given":"S.","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Previs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Orbegoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Karkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-1408","authenticated-orcid":false,"given":"R.","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-105X","authenticated-orcid":false,"given":"G.","family":"Werutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3309","authenticated-orcid":false,"given":"K.S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib2","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S1470-2045(21)00720-8","article-title":"Cancer in sub-Saharan Africa: a Lancet Oncology Commission","volume":"23","author":"Ngwa","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-023-00248-1","article-title":"From incidence to intervention: a comprehensive look at breast cancer in South Africa","volume":"12","author":"Dlamini","year":"2023","journal-title":"Oncol Ther"},{"key":"10.1016\/j.esmoop.2024.103373_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650117","article-title":"Cancer in Africa: the untold story","volume":"11","author":"Hamdi","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib5","first-page":"52","article-title":"Enrollment and racial disparities in National Cancer Institute cancer treatment clinical trials in North Carolina","volume":"77","author":"Zullig","year":"2016","journal-title":"N\u00a0C Med J"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","article-title":"Representation of minorities and women in oncology clinical trials: review of the past 14 years","volume":"14","author":"Duma","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103373_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103373_bib8","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1002\/cncr.32495","article-title":"Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research","volume":"125","author":"Behring","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103373_bib9","series-title":"Drug trial snapshots summary report 2021","year":"2022"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2022.03.015","article-title":"Gender, age, racial and ethnic disparities in clinical trial enrollment for primary liver cancer","volume":"163","author":"Jan","year":"2022","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103373_bib11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.annonc.2023.09.3107","article-title":"Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company\u2019s data collection, reporting, and interpretation of race and ethnicity","volume":"34","author":"Candelario","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103373_bib12","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050275","article-title":"Tackling the lack of diversity in cancer research","volume":"16","author":"Molina-Aguilar","year":"2023","journal-title":"Dis Model Mech"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103373_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.35714","article-title":"Clinical trial enrollment, ineligibility, and reasons for decline in older vs younger patients with cancer in the National Cancer Institute Community Oncology Research Program","volume":"5","author":"Sedrak","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12910-023-00987-w","article-title":"Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting","volume":"24","author":"Patel","year":"2023","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.esmoop.2024.103373_bib15","series-title":"Drug trials snapshots summary report 2018","author":"Woodcock","year":"2019"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103373_bib16","article-title":"Gender and sex disparity in cancer trials","volume":"5","author":"Lee","year":"2020","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103373_bib17","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/cncr.33533","article-title":"Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: a systematic review-based cohort study","volume":"127","author":"Dymanus","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103373_bib18","first-page":"1","article-title":"Disparities in breast, lung, and cervical cancer trials worldwide","volume":"4","author":"Ramaswami","year":"2018","journal-title":"J\u00a0Glob Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaoncol.2020.7478","article-title":"An analysis of contemporary oncology randomized clinical trials from low\/middle-income vs high-income countries","volume":"7","author":"Wells","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103373_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.6004\/jnccn.2022.7029","article-title":"Regional variations in clinical trial outcomes in oncology","volume":"20","author":"Wilson","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103373_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.27252","article-title":"Participation of lower and upper middle\u2013income countries in oncology clinical trials led by high-income countries","volume":"5","author":"Rubagumya","year":"2022","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib22","doi-asserted-by":"crossref","first-page":"e842","DOI":"10.1097\/HS9.0000000000000842","article-title":"A\u00a0lack of diversity, equity, and inclusion in clinical research has direct impact on patient care","volume":"7","author":"El-Galaly","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103373_bib23","article-title":"Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center","volume":"41","author":"Davidson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40487-023-00254-3","article-title":"Diversity in oncology clinical trials: current landscape for industry-sponsored clinical trials in Asia","volume":"12","author":"Habr","year":"2024","journal-title":"Oncol Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/eahr.500090","article-title":"American Indian and Alaska Native enrollment in clinical studies in the National Institutes of Health\u2019s Intramural Research Program","volume":"43","author":"Vigil","year":"2021","journal-title":"Ethics Hum Res"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103373_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00117","article-title":"Action for increasing diversity, market access, and capacity in oncology registration trials\u2014is Africa the answer? Report from a satellite session of the Accelerating Anti-Cancer Agent Development and Validation Workshop","author":"Kizub","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/curroncol30010050","article-title":"Current scenario of clinical cancer research in Latin America and the Caribbean","volume":"30","author":"G\u00f6ssling","year":"2023","journal-title":"Curr Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103373_bib28","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12877-023-03886-2","article-title":"Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Geriatr"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103373_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ijgc-2022-003614","article-title":"Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis","volume":"32","author":"Maiorano","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103373_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","article-title":"Comprehensive characterization of molecular differences in cancer between male and female patients","volume":"29","author":"Yuan","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2018.10.021","article-title":"Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores","volume":"152","author":"Spencer","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib34","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1634\/theoncologist.2019-0871","article-title":"Exclusion of men from randomized phase III breast cancer clinical trials","volume":"25","author":"Corrigan","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103373_bib35","series-title":"Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus, or hepatitis C virus infections","year":"2020"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103373_bib36","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3332\/ecancer.2021.1161","article-title":"Geographic disparities in access to cancer clinical trials in India","volume":"15","author":"Chakraborty","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.esmoop.2024.103373_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100718","article-title":"Sociodemographic diversity in cancer clinical trials: new findings on the effect of race and ethnicity","volume":"21","author":"Meyer","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103373_bib39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.20.02602","article-title":"Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials","volume":"39","author":"Unger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib40","series-title":"Cancer clinical trial eligibility criteria: available therapy in non-curative settings","year":"2022"},{"key":"10.1016\/j.esmoop.2024.103373_bib41","series-title":"Evaluating cancer drugs in patients with central nervous system metastases","year":"2021"},{"key":"10.1016\/j.esmoop.2024.103373_bib42","series-title":"Premenopausal women with breast cancer: developing drugs for treatment","year":"2021"},{"key":"10.1016\/j.esmoop.2024.103373_bib43","series-title":"Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry","year":"2022"},{"key":"10.1016\/j.esmoop.2024.103373_bib44","series-title":"Male breast cancer: developing drugs for treatment","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib45","series-title":"Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus, or hepatitis C virus infections","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib46","article-title":"Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies","year":"2020","journal-title":"FDA guidance document"},{"key":"10.1016\/j.esmoop.2024.103373_bib47","series-title":"Cancer clinical trial eligibility criteria: brain metastases","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib48","series-title":"Cancer clinical trial eligibility criteria: minimum age considerations for inclusion of pediatric patients","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib49","series-title":"Considerations for the inclusion of adolescent patients in adult oncology clinical trials. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib50","series-title":"Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs guidance for industry","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103373_bib53","series-title":"Postmarketing requirements and commitments: introduction","year":"2018"},{"key":"10.1016\/j.esmoop.2024.103373_bib60","series-title":"ICH E8 General considerations for clinical studies - scientific guideline","year":"2018"},{"key":"10.1016\/j.esmoop.2024.103373_bib62","series-title":"Department-related Parliamentary Standing Committee on Health and Family Welfare. Fifty-Ninth Report on the Functioning of the Central Drugs Standard Control Organisation (CDSCO)","year":"2012"},{"key":"10.1016\/j.esmoop.2024.103373_bib69","series-title":"Decentralized clinical trials for drugs, biological products, and devices","year":"2023"},{"key":"10.1016\/j.esmoop.2024.103373_bib70","first-page":"1","article-title":"The Diversity Site Assessment Tool (DSAT), reliability and validity of the industry gold standard for establishing investigator site ranking","volume":"7","author":"Foster","year":"2020","journal-title":"Int J Med Sci"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103373_bib72","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2101627","article-title":"A\u00a0hidden opportunity\u2014Medicaid\u2019s role in supporting equitable access to clinical trials","volume":"384","author":"Takvorian","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103373_bib73","first-page":"23","article-title":"Can just-in-time clinical trials reduce disparities in participation?","volume":"11","author":"Patel","year":"2022","journal-title":"Targeted Ther Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib74","first-page":"6","article-title":"From \u201cbrave spaces\u201d to battling bias in patient engagement","volume":"32","author":"Moultrie","year":"2023","journal-title":"Appl Clin Trials"},{"key":"10.1016\/j.esmoop.2024.103373_bib81","author":"Eve"},{"key":"10.1016\/j.esmoop.2024.103373_bib91","article-title":"Role of decentralized clinical trials in cancer drug development: results from a survey of oncologists and patients","volume":"8","author":"de las Heras","year":"2022","journal-title":"Digit Health"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib92","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/OP.22.00702","article-title":"Meeting trial participants where they are: decentralized clinical trials as a patient-centered paradigm for enhancing accrual and diversity in surgical and multidisciplinary trials in oncology","volume":"19","author":"Adesoye","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib93","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-020-04613-7","article-title":"Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process","volume":"21","author":"Witham","year":"2020","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103373_bib94","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1200\/OP.22.00560","article-title":"Increasing racial and ethnic equity, diversity, and inclusion in cancer treatment trials: evaluation of an ASCO-Association of Community Cancer Centers site self-assessment","volume":"19","author":"Guerra","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2024.103373_bib95","article-title":"The sex and gender equity in research (SAGER) guidelines: implementation and checklist development","volume":"48","author":"Epps","year":"2022","journal-title":"Eur Sci Ed"},{"issue":"15","key":"10.1016\/j.esmoop.2024.103373_bib96","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMe2114651","article-title":"Striving for diversity in research studies","volume":"385","author":"Rubin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.12.019","article-title":"New at Cell Press: the inclusion and diversity statement","volume":"184","author":"Sweet","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103373_bib98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-016-1384-3","article-title":"A\u00a0review of approaches to improve participation of culturally and linguistically diverse populations in clinical trials","volume":"17","author":"Hughson","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2024.103373_bib99","article-title":"Barriers for cancer clinical trial enrollment: a qualitative study of the perspectives of healthcare providers","volume":"28","author":"Kumar","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103373_bib100","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib101","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jtho.2018.02.013","article-title":"Making lung cancer clinical trials more inclusive: recommendations for expanding eligibility criteria","volume":"13","author":"Bonomi","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103373_bib102","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/jnci\/djac152","article-title":"Implementing modernized eligibility criteria in US National Cancer Institute clinical trials","volume":"114","author":"Denicoff","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103373_bib103","author":"Clampet"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.103373_bib105","article-title":"Impact of community outreach programme on improving cancer related preventive health behaviour","volume":"32","author":"Niranjan","year":"2022","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.esmoop.2024.103373_bib106","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/GO.20.00346","article-title":"Reimagining global oncology clinical trials for the postpandemic era: a call to arms","volume":"6","author":"Saini","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib107","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103373_bib108","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JOP.2015.005934","article-title":"Increasing minority enrollment onto clinical trials: practical strategies and challenges emerge from the NRG oncology accrual workshop","volume":"11","author":"Brooks","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103373_bib109","first-page":"202","article-title":"Pull up a seat: engaging patients as empowered partners in health equity transformation","volume":"13","author":"Karmo","year":"2022","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2023.41.16_suppl.1089","article-title":"The case for acceleration of prospective multi-stakeholder led community-based research in young Black women with triple negative breast cancer (TNBC)","volume":"41","author":"Regnante","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103373_bib111","article-title":"Partnering with patients and caregivers in cancer care: lessons from experiences with transgender, Hispanic, and pediatric populations","volume":"43","author":"Katz","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmoop.2024.103373_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cct.2015.07.007","article-title":"Using e-technologies in clinical trials","volume":"45","author":"Rosa","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.esmoop.2024.103373_bib113","article-title":"Patient-reported outcomes, digital health, and the quest to improve health equity","volume":"43","author":"Pritchett","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103373_bib114","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.33905","article-title":"Strategies to improve diversity, equity, and inclusion in clinical trials","volume":"128","author":"Kahn","year":"2022","journal-title":"Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924011414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924011414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:20Z","timestamp":1762598660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924011414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2059702924011414"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103373","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103373"}}